HRP20140611T1 - Inhibitori kinaze p70 s6 - Google Patents

Inhibitori kinaze p70 s6 Download PDF

Info

Publication number
HRP20140611T1
HRP20140611T1 HRP20140611AT HRP20140611T HRP20140611T1 HR P20140611 T1 HRP20140611 T1 HR P20140611T1 HR P20140611A T HRP20140611A T HR P20140611AT HR P20140611 T HRP20140611 T HR P20140611T HR P20140611 T1 HRP20140611 T1 HR P20140611T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
intended
trifluoromethyl
Prior art date
Application number
HRP20140611AT
Other languages
English (en)
Croatian (hr)
Inventor
Robert Dean Dally
Jianping Huang
Sajan Joseph
Timothy Alan Shepherd
Christian L. Holst
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20140611T1 publication Critical patent/HRP20140611T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20140611AT 2007-05-11 2008-05-01 Inhibitori kinaze p70 s6 HRP20140611T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91733107P 2007-05-11 2007-05-11
PCT/US2008/062143 WO2008140947A1 (en) 2007-05-11 2008-05-01 P70 s6 kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20140611T1 true HRP20140611T1 (hr) 2014-08-15

Family

ID=39765082

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140611AT HRP20140611T1 (hr) 2007-05-11 2008-05-01 Inhibitori kinaze p70 s6

Country Status (33)

Country Link
US (2) US8093383B2 (cg-RX-API-DMAC10.html)
EP (1) EP2148880B1 (cg-RX-API-DMAC10.html)
JP (1) JP5503532B2 (cg-RX-API-DMAC10.html)
KR (1) KR101088219B1 (cg-RX-API-DMAC10.html)
CN (1) CN101679439B (cg-RX-API-DMAC10.html)
AR (1) AR066344A1 (cg-RX-API-DMAC10.html)
AU (1) AU2008251692B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0811212A2 (cg-RX-API-DMAC10.html)
CA (1) CA2687265C (cg-RX-API-DMAC10.html)
CL (1) CL2008001230A1 (cg-RX-API-DMAC10.html)
CO (1) CO6241109A2 (cg-RX-API-DMAC10.html)
CR (1) CR11106A (cg-RX-API-DMAC10.html)
DK (1) DK2148880T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2009000257A (cg-RX-API-DMAC10.html)
EA (1) EA016445B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP099721A (cg-RX-API-DMAC10.html)
ES (1) ES2483726T3 (cg-RX-API-DMAC10.html)
GT (1) GT200900292A (cg-RX-API-DMAC10.html)
HR (1) HRP20140611T1 (cg-RX-API-DMAC10.html)
IL (1) IL201564A (cg-RX-API-DMAC10.html)
MA (1) MA31433B1 (cg-RX-API-DMAC10.html)
MX (1) MX2009012075A (cg-RX-API-DMAC10.html)
MY (1) MY154898A (cg-RX-API-DMAC10.html)
NZ (1) NZ580423A (cg-RX-API-DMAC10.html)
PE (1) PE20090887A1 (cg-RX-API-DMAC10.html)
PL (1) PL2148880T3 (cg-RX-API-DMAC10.html)
PT (1) PT2148880E (cg-RX-API-DMAC10.html)
RS (1) RS53451B (cg-RX-API-DMAC10.html)
SI (1) SI2148880T1 (cg-RX-API-DMAC10.html)
TN (1) TN2009000446A1 (cg-RX-API-DMAC10.html)
TW (1) TWI423805B (cg-RX-API-DMAC10.html)
UA (1) UA99284C2 (cg-RX-API-DMAC10.html)
WO (1) WO2008140947A1 (cg-RX-API-DMAC10.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
US8252791B2 (en) * 2008-08-13 2012-08-28 Jenrin Discovery, Inc. Purine compounds as cannabinoid receptor blockers
AU2009314336B2 (en) 2008-11-11 2013-09-12 Eli Lilly And Company P70 S6 kinase inhibitor and EGFR inhibitor combination therapy
CA2743242A1 (en) * 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
KR101699991B1 (ko) 2009-02-11 2017-01-26 메르크 파텐트 게엠베하 신규의 아미노 아자헤테로시클릭 카르복사미드
EA020302B1 (ru) 2009-08-07 2014-10-30 Мерк Патент Гмбх Новые азагетероциклические соединения
ES2465094T3 (es) 2009-10-23 2014-06-05 Eli Lilly And Company Inhibidores de AKT
JP6114554B2 (ja) 2010-02-03 2017-04-12 シグナル ファーマシューティカルズ,エルエルシー Torキナーゼ阻害剤に対する感受性についての予測的なバイオマーカーとしてのlkb1変異の同定
WO2012016001A1 (en) 2010-07-29 2012-02-02 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
KR101894116B1 (ko) 2010-11-24 2018-08-31 메르크 파텐트 게엠베하 퀴나졸린 카르복사미드 아제티딘
EP2755965B1 (en) * 2011-09-12 2017-07-26 Merck Patent GmbH Novel imidazole amines as modulators of kinase activity
CN103930407B (zh) 2011-09-12 2019-02-26 默克专利有限公司 用作激酶活性调节剂的氨基嘧啶衍生物
MX2015002887A (es) * 2012-09-06 2015-07-06 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CA2890345A1 (en) * 2012-11-16 2014-05-22 Merck Patent Gmbh Imidazol-piperidinyl derivatives as modulators of kinase activity
ES2620119T3 (es) 2012-11-16 2017-06-27 Merck Patent Gmbh Derivados heterocíclicos novedosos como moduladores de la actividad de quinasa
WO2014085528A1 (en) 2012-11-29 2014-06-05 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
HK1218756A1 (zh) 2013-03-11 2017-03-10 默克专利有限公司 用作激酶活性调节剂的6-[4-(1h-咪唑-2-基)哌啶-1-基]嘧啶-4-胺衍生物
SG10201708111YA (en) 2013-04-17 2017-11-29 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ,エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
TW201521725A (zh) 2013-04-17 2015-06-16 Signal Pharm Llc 使用tor激酶抑制劑組合療法以治療癌症之方法
CA2909629C (en) 2013-04-17 2022-12-13 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
MX377267B (es) 2013-04-17 2025-03-07 Signal Pharm Llc Tratamiento de cáncer con dihidropirazino-pirazinas.
TWI631949B (zh) 2013-04-17 2018-08-11 標誌製藥公司 使用tor激酶抑制劑組合療法以治療癌症之方法
CA3143529A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2015240094B2 (en) 2014-04-03 2020-07-30 Merck Patent Gmbh Combinations of cancer therapeutics
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2016040078A1 (en) * 2014-09-10 2016-03-17 Eli Lilly And Company Substituted phenyl imidazolyl piperidyl compounds as p70s6k1 inhibitors
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
BR112019027402A2 (pt) 2017-06-22 2020-07-07 Celgene Corporation tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b
EP4243819A1 (en) 2020-11-16 2023-09-20 Merck Patent GmbH Kinase inhibitor combinations for cancer treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
CA2563699C (en) * 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス, インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター(p70S6K、Akt−1およびAkt−2)としての[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジンまたは[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジン化合物
EP1907383A1 (en) 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
EP3421471B1 (en) 2006-04-25 2021-05-26 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
CO6241109A2 (es) 2011-01-20
UA99284C2 (ru) 2012-08-10
TW200848053A (en) 2008-12-16
CN101679439B (zh) 2013-09-11
SI2148880T1 (sl) 2014-07-31
ECSP099721A (es) 2009-12-28
BRPI0811212A2 (pt) 2014-10-29
TWI423805B (zh) 2014-01-21
AU2008251692B2 (en) 2012-10-11
RS53451B (sr) 2014-12-31
WO2008140947A1 (en) 2008-11-20
EA016445B1 (ru) 2012-05-30
ES2483726T3 (es) 2014-08-07
CN101679439A (zh) 2010-03-24
KR101088219B1 (ko) 2011-11-30
TN2009000446A1 (en) 2011-03-31
MX2009012075A (es) 2009-11-19
CR11106A (es) 2010-04-12
PT2148880E (pt) 2014-08-28
JP2010526814A (ja) 2010-08-05
DOP2009000257A (es) 2010-03-31
DK2148880T3 (da) 2014-06-16
AU2008251692A1 (en) 2008-11-20
EP2148880A1 (en) 2010-02-03
CA2687265C (en) 2012-12-04
HK1140767A1 (en) 2010-10-22
US20120071490A1 (en) 2012-03-22
JP5503532B2 (ja) 2014-05-28
GT200900292A (es) 2011-06-24
IL201564A0 (en) 2010-05-31
US8093383B2 (en) 2012-01-10
NZ580423A (en) 2012-02-24
AR066344A1 (es) 2009-08-12
MA31433B1 (fr) 2010-06-01
EA200971051A1 (ru) 2010-06-30
IL201564A (en) 2014-08-31
EP2148880B1 (en) 2014-05-28
CA2687265A1 (en) 2008-11-20
CL2008001230A1 (es) 2009-05-22
PE20090887A1 (es) 2009-07-13
US20090163714A1 (en) 2009-06-25
MY154898A (en) 2015-08-28
KR20100005710A (ko) 2010-01-15
PL2148880T3 (pl) 2014-10-31

Similar Documents

Publication Publication Date Title
HRP20140611T1 (hr) Inhibitori kinaze p70 s6
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
MY150519A (en) Imidazoquinolines with immuno-modulating properties
CO6341631A2 (es) Derivados de 1,2,4 - oxadiazol y su uso terapéutico
MX2020008570A (es) Inhibidores de arginasa y sus metodos de uso.
NZ597533A (en) Apoptosis signal-regulating kinase inhibitors
HRP20221154T1 (hr) Supstituirani pirazolo[1,5-a]piridinski spojevi kao inhibitori ret kinaze
MX2009011812A (es) Aminopirimidinas utiles como inhibidores de cinasa.
SE0402735D0 (sv) Novel compounds
GEP20156267B (en) 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
EA200800815A1 (ru) 2-анилин-4-арилзамещенные тиазольные производные
WO2008115098A3 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
ZA200708159B (en) 1-Acetic acid-indole derivatives with PDG2 antagonist activity
NZ588994A (en) Phenyl and benzodioxinyl substituted indazoles derivatives
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
HRP20131051T1 (hr) Inhibitori proteinskih kinaza
NO20090216L (no) Forbindelser med CRTH2 antagonistaktivitet
AR092289A1 (es) Derivados de aminoquinazolina y sus sales y metodos de uso
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
TW200738706A (en) Pyrido-, pyrazo-and pyrimido-pyrimidine derivatives and their use as mTOR inhibitors
BRPI0506765A (pt) composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
CA2406392A1 (en) Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof